Dexamethasone/pomalidomide/trametinib

  • PDF / 169,332 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 71 Downloads / 160 Views

DOWNLOAD

REPORT


1 S

Diarrhoea, pancytopenia and infections: case report In a study of 14 patients referred November 2018 and May 2019, a woman [age not stated] was described, who developed diarrhoea, infections and pancytopenia during treatment with dexamethasone, pomalidomide and off-label trametinib for multiple myeloma. The woman, who was diagnosed with multiple myeloma and extra-medullary disease, started receiving seventh-line treatment with dexamethasone, pomalidomide and off-label trametinib [routes and dosages not stated]. However, she developed diarrhoea, infections and pancytopenia. The woman’s treatment was interrupted due to infection [duration of treatments to reaction onsets and outcomes not stated]. After four months, she died [cause of death not stated]. Seval GC, et al. Next generation sequencing may be helpful in designing novel combinations among heavily pretreated myeloma patients, refractory to all available approved 803447603 anti-myeloma drugs. Blood 134 (Suppl. 1): 3197, Nov 2019. Available from: URL: http://doi.org/10.1182/blood-2019-127541 [abstract]

0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 18 Jan 2020 No. 1787

Data Loading...